[1]Zhang J., Walsh M.F., Wu G. Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med. 2015;373:2336-2346.
[2]Lee P., Bhansali R., Izraeli S. The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome. Leukemia. 2016;30:1816-1823.
[3]Roberts I., Izraeli S. Haematopoietic development and leukaemia in Down syndrome. Br J Haematol. 2014;167:587-599.
[4]Li Y., Schwab C., Ryan S. Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature. 2014;508:98-102.
[5]Harrison C.J., Schwab C. Constitutional abnormalities of chromosome 21 predispose to iAMP21-acute lymphoblastic leukaemia. Eur J Med Genet. 2016;59:162-165.
[6]Zhang M.Y., Churpek J.E., Keel S.B. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet. 2015;47:180-185.
[7]Noetzli L., Lo R.W., Lee-Sherick A.B. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat. Genet. 2015;47:535-538.
[8]Topka S., Vijai J., Walsh M.F. Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia. PLoS Genet. 2015;11:e1005262.
[9]Poggi M., Canault M., Favier M. Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors. Haematologica. 2017;102:282-294.
[10]Moriyama T., Metzger M.L., Wu G. Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: A systematic genetic study. Lancet Oncol. 2015;16:1659-1666.
[11]Auer F., Rüschendorf F., Gombert M. Inherited susceptibility to pre B-ALL caused by germline transmission of PAX5 c.547G>A. Leukemia. 2014;28:1136-1138.
[12]Shah S., Schrader K.A., Waanders E. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet. 2013;45:1226-1231.
[13]Preudhomme C., Renneville A., Bourdon V. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood. 2009;113:5583-5587.
[14]Kuehn H.S., Boisson B., Cunningham-Rundles C. Loss of B Cells in Patients with Heterozygous Mutations in IKAROS. N Engl J Med. 2016;374:1032-1043.
[15]Holmfeldt L., Wei L., Diaz-Flores E. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45:242-252.
[16]Hof J., Krentz S., Schewick C., van. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childshood acute lymphoblastic leukemia. J Clin Oncol. 2011;29:3185-3193.
[17]Alter B.P. Fanconi anemia and the development of leukemia. Best Pract Res Clin Haematol. 2014;27:214-221.
[18]Schoenaker M.H.D., Suarez F., Szczepanski T. Treatment of acute leukemia in children with ataxia telangiectasia (A-T). Eur J Med Genet. 2016;59:641-646.
[19]Arora H., Chacon A.H., Choudhary S. Bloom syndrome. Int J Dermatol. 2014;53:798-802.
[20]Ripperger T., Schlegelberger B. Acute lymphoblastic leukemia and lymphoma in the context of constitutional mismatch repair deficiency syndrome. Eur J Med Genet. 2016;59:133-142.
[21]Chao M.M., Todd M.A., Kontny U. T-cell acute lymphoblastic leukemia in association with Börjeson-Forssman-Lehmann syndrome due to a mutation in PHF6. Pediatr Blood Cancer. 2010;55:722-724.
[22]Cavé H., Caye A., Strullu M. Acute lymphoblastic leukemia in the context of RASopathies. Eur J Med Genet. 2016;59:173-178.
[23]Perez-Garcia A., Ambesi-Impiombato A., Hadler M. Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood. 2013;122:2425-2432.
[24]Sekeres M.A. The epidemiology of myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010;24:287-294.
[25]Wagner J.E., Tolar J., Levran O. Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. Blood. 2004;103:3226-3229.
[26]Alter B.P., Giri N., Savage S.A. Cancer in dyskeratosis congenita. Blood. 2009;113:6549-6557.
[27]Dror Y., Squire J., Durie P. Malignant myeloid transformation with isochromosome 7q in Shwachman-Diamond syndrome. Leukemia. 1998;12:1591-1595.
[28]Myers K.C., Davies S.M., Shimamura A. Clinical and molecular pathophysiology of Shwachman-Diamond syndrome: an update. Hematol Oncol Clin North Am. 2013;27:117-128.
[29]Freedman M.H., Alter B.P. Risk of myelodysplastic syndrome and acute myeloid leukemia in congenital neutropenias. Semin Hematol. 2002;39:128-133.
[30]Shannon K.M., Turhan A.G., Chang S.S. Familial bone marrow monosomy 7. Evidence that the predisposing locus is not on the long arm of chromosome 7. J Clin Invest. 1989;84:984-989.
[31]Felix C.A., Hosler M.R., Provisor D. The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood. 1996;87:4376-4381.
[32]Schlegelberger B., Kreipe H., Lehmann U. A child with Li-Fraumeni syndrome: Modes to inactivate the second allele of TP53 in three different malignancies. Pediatr Blood Cancer. 2015;62:1481-1484.
[33]Narumi S., Amano N., Ishii T. SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7. Nat Genet. 2016;48:792-797.
[34]Tesi B., Davidsson J., Voss M. Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms. Blood. 2017;129:2266-2279.
[35]Wlodarski M.W., Hirabayashi S., Pastor V. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood. 2016;127:1387-1397.
[36]Wimmer K., Kratz C.P. Constitutional mismatch repair-deficiency syndrome. Haematologica. 2010;95:699-701.
[37]Song W.J., Sullivan M.G., Legare R.D. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23:166-175.
[38]Antony-Debré I., Duployez N., Bucci M. Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia. Leukemia. 2016;30:999-1002.
[40]Niemeyer C.M., Kang M.W., Shin D.H. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet. 2010;42:794-800.
[41]Flotho C., Steinemann D., Mullighan C.G. Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11. Oncogene. 2007;26:5816-5821.
[42]Side L., Taylor B., Cayouette M. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med. 1997;336:1713-1720.
[43]Tartaglia M., Niemeyer C.M., Fragale A. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 2003;34:148-150.
[44]Mao G.F., Goldfinger L.E., Fan D.C. Dysregulation of PLDN (pallidin) is a mechanism for platelet dense granule deficiency in RUNX1 haplodeficiency. J Thromb Haemost JTH. 2017;15:792-801.
[45]Zierhut H., Schneider K.W. Stem Cell Transplantation: Genetic Counselors as a Critical Part of the Process. Curr Genet Med Rep. 2014;2:39-47.
[46]Porter C.C., Druley T.E., Erez A. Recommendations for Surveillance for Children with Leukemia-Predisposing Conditions. Clin Cancer Res. 2017;23:e14-e22.
[47]Ripperger T., Bielack S.S., Borkhardt A. Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. Am J Med Genet A. 2017;173:1017-1037.
[48]Furutani E., Shimamura A. Germline Genetic Predisposition to Hematologic Malignancy. J Clin Oncol. 2017;35:1018-1028.
[49]Babushok D.V., Bessler M., Olson T.S. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults. Leuk Lymphoma. 2016;57:520-536.